Home › Blood Cancers › NCT07133074

Allergy Delabeling in Antibiotic Stewardship - Intervention

Optimizing Antibiotic Selection in Hematologic Malignancy Patients With Reported Beta-lactam Allergy - Intervention

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service
* reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and/or carbapenem)

Exclusion Criteria:

* patients with a history of severe cutaneous adverse reaction
* patients with a history of Stevens-Johnson syndrome
* patients with a history of toxic epidermal necrolysis
* patients with a history of drug-induced exfoliative dermatitis
* patients with a history of drug reaction with eosinophilia and systemic symptoms
* patients with a history of acute generalized exanthematous pustulosis

About the study

The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.

What is being tested

• RENEW-IN Algorithm for assessment of a beta-lactam intervention (diagnostic test)
• EMR Review (other)

Sponsor: Abramson Cancer Center at Penn Medicine · Participants: 3,800 · Started: Apr 20, 2026

Contact the study team

• Ebbing Lautenbach, MD,MPH,MSCE · Phone: 215-898-6977

Official record on ClinicalTrials.gov — NCT07133074

Locations in the U.S.

Conditions

• Blood Cancers

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.